Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 93, Issue 3, Pages 252-259Publisher
WILEY
DOI: 10.1038/clpt.2012.237
Keywords
-
Categories
Funding
- Cancer Research UK [C309/A8725]
- Cancer Research UK through the Stratified Medicine Programme [C21807/A13641]
- National Institute of Health Research
- Cancer Research UK [11566] Funding Source: researchfish
Ask authors/readers for more resources
The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational development of targeted drugs for patient populations stratified by genetic characteristics. Here we discuss general challenges relating to molecular diagnostics and describe predictive biomarkers for personalized cancer medicine. We also highlight resistance mechanisms for epidermal growth factor receptor (EGFR) kinase inhibitors in lung cancer. We envisage a future requiring the use of longitudinal genome sequencing and other omics technologies alongside combinatorial treatment to overcome cellular and molecular heterogeneity and prevent resistance caused by clonal evolution.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available